Valuation: Castle Biosciences, Inc.

Market Cap 729M 637M 589M 540M 1.02B 70.2B 1.04B 7.02B 2.76B 34.28B 2.74B 2.68B 118B P/E 2026 *
-17x
P/E 2027 * -25.1x
Enterprise Value 729M 637M 589M 540M 1.02B 70.2B 1.04B 7.02B 2.76B 34.28B 2.74B 2.68B 118B EV / Sales 2026 *
2.07x
EV / Sales 2027 * 1.85x
Free-Float
97.27%
Yield 2026 *
-
Yield 2027 * -
1 day+0.73%
1 week-1.49%
Current month+1.45%
1 month+18.26%
3 months-1.49%
6 months-39.53%
Current year-37.80%
1 week 22.46
Extreme 22.46
25.13
1 month 19.86
Extreme 19.855
25.13
Current year 17.72
Extreme 17.722
44.28
1 year 14.59
Extreme 14.59
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.58
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 31/08/2007
Director of Finance/CFO 56 30/11/2017
Chief Tech/Sci/R&D Officer - 30/06/2021
Director TitleAgeSince
Director/Board Member 64 31/08/2007
Chairman 64 31/08/2014
Director/Board Member 70 05/12/2018
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Fiscal year

Founder

22,264 0.0734%
01/07/26 Sell

Chief Operating Officer

-8,586 0.0283%
16/06/26 Sell

Chief Operating Officer

-8,587 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%-1.49%+29.52%+46.64% 729M
-4.88%-5.53%+224.21%+309.31% 21.61B
+1.18%+5.13%-38.55%-22.61% 9.69B
+0.75%-0.89%+41.18%+20.19% 6.79B
-2.78%+3.31%+259.94%-24.53% 5.81B
+2.44%+9.01%-16.48%-28.79% 5.1B
-5.61%-7.89%-47.58% - 4.94B
+0.46%+4.81%-22.64%-25.61% 4.21B
+7.48%+20.79%+83.44%+108.39% 4.15B
+2.00%+7.26%-11.87%-39.00% 2.74B
Average +0.17%+6.81%+50.12%+38.22% 6.58B
Weighted average by Cap. -1.24%+6.06%+94.00%+108.20%

Financials

2026 *2027 *
Net sales 352M 308M 285M 261M 495M 33.95B 503M 3.4B 1.33B 16.58B 1.32B 1.29B 57.23B 393M 343M 318M 291M 552M 37.86B 561M 3.79B 1.49B 18.49B 1.48B 1.44B 63.83B
Net income -43.46M -37.99M -35.14M -32.24M -61.02M -4.19B -62.08M -419M -165M -2.05B -163M -160M -7.06B -26.06M -22.78M -21.06M -19.33M -36.58M -2.51B -37.22M -251M -98.68M -1.23B -97.85M -95.7M -4.23B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
942
Date Price Change Volume
16/07/26 US$24.23 +0.87% 375,691
15/07/26 US$24.02 +3.89% 188,232
14/07/26 US$23.12 +0.61% 251,257
13/07/26 US$22.98 -3.12% 269,909
10/07/26 US$23.72 -3.42% 207,334
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.02USD
Average target price
42.78USD
Spread / Average Target
+78.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock